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Abstract
Background: In our present study, we studied the role of demyelination of the trigeminal nerve root in the
development of prolonged nociceptive behavior in the trigeminal territory.
Results: Under anesthesia, the Sprague-Dawley rats were mounted onto a stereotaxic frame and 3 μLo f
lysophosphatidic acid (LPA, 1 nmol) was injected into the trigeminal nerve root to produce demyelination. This
treatment decreased the air-puff thresholds, persisted until postoperative day 130, and then returned to the
preoperative levels 160 days after LPA injection. The LPA-treated rats also showed a significant hyper-
responsiveness to pin-prick stimulation. We further investigated the antinociceptive and neuroprotective effects of
progesterone in rats undergoing demyelination of the trigeminal nerve root. Progesterone (8, 16 mg/kg/day) was
administered subcutaneously, beginning on the operative day, for five consecutive days in the LPA-treated rats.
Treatment with progesterone produced significant early anti-allodynic effects and delayed prolonged anti-allodynic
effects. The expression of protein zero (P0) and peripheral myelin protein 22 (PMP22) were significantly down-
regulated in the trigeminal nerve root on postoperative day 5 following LPA injection. This down-regulation of the
P0 and PMP22 levels was blocked by progesterone treatment.
Conclusions: These results suggest that progesterone produces antinociceptive effects through neuroprotective
action in animals with LPA-induced trigeminal neuropathic pain. Moreover, progesterone has potential utility as a
novel therapy for trigeminal neuropathic pain relief at an appropriate managed dose and is therefore a possible
future treatment strategy for improving the recovery from injury.
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Background
Progesterone is a female gonadal steroid hormone
synthesized in the ovary that exerts a wide range of
actions against its target tissues including the uterus,
mammary glands and brain. There is however abundant
evidence now that progesterone has functions that go
beyond its role as a female sex hormone. Exogenous
progesterone and its derivates have been shown to be a
successful treatment for rat models of traumatic brain
injury and stroke [1-4], and peripheral neuropathy
[5-10]. Progesterone also reduces neuronal cell death
[11] and attenuates neurological abnormalities after
ischemia [12-14] and spinal cord injury [15]. These
results suggest that progesterone or some of its metabo-
lites can be successfully used to treat traumatic brain
and spinal cord injury, as well as ischemic stroke.
Therefore, the neurotrophic and neuroprotective effects
of this hormone have attracted much attention because
of their therapeutic promise.
* Correspondence: dkahn@knu.ac.kr
1Department of Oral Physiology, School of Dentistry, Kyungpook National
University, Daegu (700-422), South Korea
Full list of author information is available at the end of the article
Kim et al. Molecular Pain 2012, 8:16
http://www.molecularpain.com/content/8/1/16 MOLECULAR PAIN
© 2012 Kim et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.The involvement of progesterone in the modulation of
pain has been described in previous reports. In this pre-
vious study, the systemic administration of progesterone
prevented the development of mechanical allodynia and
reduced the painful responses to cold stimulation in ani-
mals subjected to a spinal cord hemisection [16]. In
contrast, the intrathecal injection of ICI 182,780, a pro-
gesterone receptor antagonist, produced antinociceptive
effects in another earlier study [17]. These controversial
results suggest that although spinal progesterone recep-
tors play an important role in neuropathic pain, the role
of this hormone in pain modulation remains unclear.
Trigeminal neuralgia is a severe chronic pain syn-
drome characterized by brief but intense stabbing or
electrical shock-like paroxysmal pain. In affected
patients, adjacent arterial loops, tumors, or arteriove-
nous malformations have been shown to compress the
trigeminal nerve root [18-20]. Previous studies from sev-
eral decades ago proposed a causal relation between the
presence of pain paroxysms and focal demyelination
with compression of the trigeminal nerve root [18,19].
Hilton and colleagues [21] observed a focal loss of mye-
lin and the demyelination of axons in the trigeminal
nerve root by vascular compression in patient with tri-
geminal neuralgia. These results suggested that demyeli-
nation in the trigeminal nerve root plays an important
role in the pathology of trigeminal neuralgia.
In our current study, we report prolonged nociceptive
behavior in a rat model following focal demyelination
produced by microinjection of lysophosphatidic acid (1-
acyl-2-lyso-sn-glycero-3-phosphate; LPA) into the tri-
geminal nerve root. This procedure is simple and the
treated animals manifest signs of chronic nociceptive
behavior, including mechanical allodynia and hyperalge-
sia, in the trigeminal territory of the affected nerve. We
also investigated the neuroprotective and antinociceptive
effects of the systemic administration of progesterone in
the LPA-treated rats. We administered progesterone
subcutaneously beginning on the operative day for five
consecutive days. After daily treatment with progester-
one, we measured changes in the air-puff thresholds and
we also monitored delayed anti-allodynic effects. Follow-
ing the final administration of progesterone, changes in
protein zero (P0) or peripheral myelin protein 22 (PMP
22) immunoreactivity were examined to evaluate its
neuroprotective effects.
Results
Our present experiments demonstrated that LPA
injected into the trigeminal nerve root of the rat pro-
duces prolonged nociceptive behavior in the trigeminal
territory of the facial area (Figure 1). Naïve rats did not
respond to a pressure of less than 40 psi. The vehicle-
treated rats showed mild decreases in air-puff thresholds
until postoperative day 30. However, the LPA-treated
group showed significantly decreased air-puff thresholds
as compared with the vehicle-treated group (F(1, 22) =
197.697, P < 0.001, Figure 1A). The mean air-puff
Figure 1 Prolonged nociceptive behavior following the
microinjection of LPA into the trigeminal nerve root of the rat.
(A) Time course analysis of changes in the air-puff thresholds. LPA-
treated animals showed significant decreased air-puff thresholds on
postoperative day 3. LPA-induced mechanical allodynia was
maintained until postoperative day 130. (B) Time course analysis of
changes in the pin-prick responses. LPA injection produced
significant mechanical hyper-responsiveness to pin-prick stimulation
compared with the vehicle-treated group. (C) Time course analysis
of changes in the thermal nociception. #P< 0.05, vehicle- vs. LPA-
treated group. All points between two identical symbols have the
same level of significance.
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after microinjection of LPA and maintained until post-
operative day 130. Air-puff thresholds recovered to their
preoperative levels at 160 days after microinjection of
LPA. We further observed mechanical hyperalgesia fol-
lowing LPA injection in our current analyses. The naïve
animals did not produce any significant responses to
pin-prick stimulation. Vehicle-treated animals showed
increased responses to pin-prick stimulation, but this
was not found to be statistically significant. However,
LPA injection produced a significant hyper-responsive-
ness to pin-prick stimulation compared to the vehicle-
treated group (F(1, 22) = 43.311, P <0 . 0 0 1 ,F i g u r e1 B ) .
On postoperative day 3, the mean response to pin prick
stimulation in the LPA-treated group (2.6 ± 0.1) was
significantly higher than that in the vehicle-treated
group (1.6 ± 0.3), which persisted until postoperative
day 100. The head withdrawal latency times did not
reveal any significant differences between the vehicle-
and LPA-treated groups (Figure 1C). Body weight was
also monitored after LPA injection. The mean body
weight of the rats treated with LPA was not significantly
different from that of the sham-treated group. All rats
gained weight steadily after surgery and no significant
differences were observed between the treatment groups
(data not shown). These results suggest that the proce-
dures we used did not produce surgical trauma or affect
body weight.
The morphological changes observed following LPA
injection into the trigeminal nerve root are illustrated in
Figure 2. The vehicle injection into the trigeminal nerve
root did not affect the axonal morphology. At the light
microscopic level, an LPA injection produced severe
demyelination of the axonal portion of the trigeminal
nerve root on postoperative day 1 (Figure 2A, B) and 14
(Figure 2C, D) compared to the vehicle-treated group,
respectively. On postoperative day 160, morphological
analysis showed that LPA-induced demyelination was
recovered (Figure 2E, F).
We observed antinociceptive effects following the
administration of progesterone in rats with demyelina-
tion of the trigeminal nerve root. Progesterone (8, 16
mg/kg/day) was injected beginning on operative day for
five consecutive days. The effects of daily treatment with
progesterone upon the air-puff thresholds are illustrated
in Figure 3. We did not monitor significant changes in
air-puff thresholds following the first treatment with
progesterone. Neither daily treatments with a low dose
of progesterone (8 mg/kg/day) nor a high dose of pro-
gesterone (16 mg/kg/day) on postoperative day 2 pro-
duced anti-allodynic effects. However, after the
administration of 16 mg of progesterone on postopera-
tive days 3, 4, and 5, significant anti-allodynic effects
could be observed (P < 0.05). Figure 4 illustrates the
delayed effects of progesterone treatment upon the
mechanical allodynia produced by LPA injection.
Neither subcutaneous injection of vehicle nor a low
dose of progesterone (8 mg/kg/day) affected mechanical
allodynia. However, the subcutaneous injection of 16 mg
of progesterone significantly reduced mechanical allody-
nia until four days after the final injection of progester-
one. Moreover, progesterone-treated animals (16 mg/kg/
day) showed delayed but significant anti-allodynic effects
on postoperative day 40, compared to the vehicle-trea-
ted group (F(1, 14) = 14.532, P < 0.002). These delayed
anti-allodynic effects persisted on postoperative day 80.
To evaluate whether an antinociceptive dose of proges-
terone is associated with motor dysfunction, a rotarod
test was performed after the subcutaneous administra-
tion of progesterone at 16 mg/kg/day. No effects on
motor function were observed throughout the treatment
period.
The effects of morphological changes observed follow-
ing progesterone treatment (16 mg/kg/day) on LPA-
induced demyelination in the trigeminal nerve root are
illustrated in Figure 5. The vehicle injection into the tri-
geminal nerve root did not inhibit LPA-induced demye-
lination of the trigeminal root. However, daily treatment
Figure 2 The morphological changes in the trigeminal nerve
root following microinjection of LPA. On postoperative day 1 (A,
B) and 14 (C, D), luxol fast blue stained light micrographs reveal
severe demyelination of axonal portion of the trigeminal nerve root
compared with vehicle-injected root, respectively (E, F). LPA-induced
demyelination was recovered on postoperative day 160. Scale bar,
50 μm.
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of the axonal portion of the trigeminal nerve root com-
pared to the vehicle-treated group.
To assess the neuroprotective effects of progesterone
against demyelination following LPA injection into the
trigeminal nerve root, we examined P0 and PMP 22
expression using immunohistochemistry and western
blotting analysis. Figure 6 ill u s t r a t e st h ec h a n g e si nP 0
expression following LPA injection, showing significant
down-regulation of this protein in the trigeminal nerve
root on postoperative day 5 compared to the naïve ani-
mals. The down-regulation of P0 expression produced
by LPA injection was blocked by progesterone treatment
(16 mg/kg/day, Figure 6A). Western blot analysis also
showed that treatment with progesterone significantly
increased the P0 expression level in LPA-injected ani-
mals (P < 0.05, Figure 6B, C).
We obtained similar results when examining PMP 22
expression (Figure 7) which was found to be signifi-
cantly down-regulated in the trigeminal nerve root on
postoperative day 5 compared to the naïve animals. The
down-regulation of PMP 22 expression produced by
LPA injection was blocked byp r o g e s t e r o n et r e a t m e n t
(16 mg/kg/day, Figure 7A). This result was confirmed
by western blot analysis (P < 0.05, Figure 7B, C).
Discussion
Our present analyses demonstrate that the injection of
LPA into the trigeminal nerve root produces severe
demyelination and prolonged nociceptive behavior in
rats. The subcutaneous administration of progesterone
alleviates nociceptive behavioral responses and demyeli-
nation in a rat model involving microinjection of LPA
into the trigeminal nerve root. These results suggest
that progesterone produces antinociceptive effects
through neuroprotective activity against trigeminal neu-
ropathic pain produced by LPA-induced demyelination.
Treatment with progesterone at an appropriate managed
dose therefore has potential utility as a novel therapy for
the relief of trigeminal neuropathic pain.
Trigeminal neuropathic pain model
LPA is generated by enzymatic cleavage of stored glyco-
phospholipids in the membranes of stimulated cells
[22,23] and exhibits diverse biological activities during
wound healing and tissue regeneration [24-26]. Inoue et
al. [27] have recently demonstrated that the intrathecal
administration of LPA produces demyelination causing
neuropathic pain in mice. The participation of LPA-
induced demyelination in the development of neuro-
pathic pain is also supported by other LPA studies
[28-30]. Moreover, LPA1 receptor knockout mice did
not produce neuropathic pain resulting from LPA injec-
tion or demyelination following a partial sciatic nerve
Figure 4 Delayed effects of progesterone treatment (8 or 16
mg/kg/day) on mechanical allodynia produced by the
microinjection of LPA into the trigeminal nerve root.
Progesterone-treated animals showed significant delayed anti-
allodynic effects. The lines denote the period of five progesterone
treatments. * P < 0.05, vehicle- vs. progesterone-treated group.
Figure 3 The acute effects of daily treatments with
progesterone (8 or 16 mg/kg/day) on mechanical allodynia in
rats microinjected with LPA into the trigeminal nerve root.
Daily treatment with a low dose of progesterone (8 mg/kg/day) did
not produce anti-allodynic effects. However, the administration of
16 mg of progesterone on postoperative days 3, 4, and 5 produced
significant anti-allodynic effects. * P < 0.05, vehicle- vs.
progesterone-treated group.
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in which LPA is injected into the trigeminal ganglion.
These LPA-treated rats show severe demyelination in
the trigeminal ganglion and significant nociceptive beha-
vior. These results indicate that receptor-mediated LPA
signaling plays a crucial role in the initiation of neuro-
pathic pain –including the orofacial area.
In our present study, we have established a trigeminal
neuropathic pain animal model involving LPA-induced
demyelination in the trigeminal nerve root. The proce-
dure is simple and the treated animals manifest signs of
chronic nociceptive behavior, including mechanical allo-
dynia and hyperalgesia, in the trigeminal territory of the
affected nerve. LPA-treated rats also show sever demye-
lination in the trigeminal nerve root and this demyelina-
tion was recovered on postoperative day 160 in the
present study. These results suggest that recovery of
mechanical allodynia, produced by LPA injection, is
caused by alleviation of demyelination in the trigeminal
nerve root. Moreover, blockade of LPA receptor inhib-
ited prolonged nociceptive behavior produced by LPA-
induced demyelination in the trigeminal ganglion of rats
[31]. These results support our findings that LPA-
induced focal demyelination in the trigeminal nerve root
produces severe and prolonged nociception.
Figure 7 Effects of progesterone treatment (16 mg/kg/day)
upon PMP22 expression. (A) Vehicle treatments did not affect the
LPA-induced decreases in PMP22 expression in the trigeminal nerve
root compared with naïve rats on postoperative day 5. However,
decreased PMP22 expression, produced by LPA injection, was
recovered following treatment with progesterone. (B) Western blot
analysis also showed that LPA suppresses the 19 kDa band for
PMP22, which was recovered by treatment with progesterone.
GAPDH was used as a loading control. (C) Quantitative analyses of
western blotting data. * P < 0.05, naive- vs. LPA/vehicle-treated
group. # P < 0.05, LPA/vehicle-treated group vs. LAP/progesterone-
treated group. Scale bar, 50 μm.
Figure 6 Effects of progesterone treatment (16 mg/kg/day)
upon P0 expression. (A) Vehicle treatment did not affect the LPA-
induced decreases in P0 expression in the trigeminal nerve root
compared with naïve rats on postoperative day 5. However,
decreased P0 expression, produced by LPA injection, was recovered
following treatment with progesterone. (B) Western blot analysis
confirmed that LPA injections cause a decrease in the 27 kDa band
for P0, which was recovered by treatment with progesterone.
GAPDH was used as a loading control. (C) Quantitative analyses of
western blotting data. * P < 0.05, naive- vs. LPA/vehicle-treated
group. # P < 0.05, LPA/vehicle-treated group vs. LPA/progesterone-
treated group. Scale bar, 50 μm.
Figure 5 The morphological changes in the trigeminal nerve root following treatment of progesterone. Luxol fast blue stained light
micrographs reveal the attenuation of demyelination of axonal portion of the trigeminal nerve root compared with vehicle-injected root after
daily treatment of progesterone (16 mg/kg/day). Scale bar, 50 μm.
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may mimic that of trigeminal neuralgia because micro-
vascular compression of the trigeminal nerve root was
recognized as a cause of trigeminal neuralgia [19]. A
focal loss of myelin of axons in the trigeminal nerve
root were later further observed in a trigeminal neural-
gia patient [21,32]. These results taken together with
our findings may demonstrate a novel and significant
animal model in which to study the trigeminal neuralgia.
Neuroprotective effects of progesterone
It is well known that the progesterone synthesized by
neurons and glial cells plays an important role in neuro-
protection and myelination as a neurosteroid. A particu-
l a r l yn o t e w o r t h yp r o p e r t yo fp r o g e s t e r o n ei st h a ti tn o t
only provides strong neuroprotection but also promotes
myelin formation, either during development or during
the remyelination of axons in adults. We here observed
neuroprotective effects of progesterone via the evalua-
tion of P0 and PMP 22 levels in the trigeminal nerve
root of LPA-treated rats. P0, a major protein component
of peripheral nerve myelin, represents between 50-70%
of the total protein and is a 28-kDa integral membrane
glycoprotein which appears to be expressed by myelinat-
ing Schwann cells, but neither by central glia, nor by the
non-myelinating Schwann cells that populate many per-
ipheral nerves. PMP22 is a smaller 22-kDa glycoprotein
that was first purified and characterized from bovine
peripheral nerve myelin. It represents 2-5% of the total
peripheral nerve myelin proteins.
The results of our present study demonstrate that
LPA injection, which produces severe demyelination,
significantly decreases the P0 and PMP 22 levels in the
trigeminal nerve root. The down-regulation of P0 and
PMP22 produced by LPA injection was blocked by pro-
gesterone treatment. These findings suggest that the sys-
temic administration of progesterone attenuates the
destruction of the myelin sheath caused by LPA injec-
tion. The neuroprotective effects of progesterone have
been extensively studied in the rat spinal cord injury
model or in the Wobbler mouse, a model of sponta-
neous motor neuron degeneration [33]. Progesterone
also exerts protective effects on axonal pathology in
experimental autoimmune encephalomyelitis, a multiple
sclerosis animal model that manifests spinal cord
demyelination [34]. The marked protective effects of
progesterone on spinal motor neurons involve the up-
regulation of brain-derived neurotrophic factor (BDNF),
a key regulator of neuronal and glial functions [35]. Exo-
genous progesterone also enhances the concentrations
of P0 and PMP22 proteins in co-cultures of dorsal root
ganglion (DRG) neurons and Schwann cells [36] and sti-
mulates the expression of their gene promoters in cul-
tured rat Schwann cells [37]. These previous results
suggest that progesterone plays an important role either
in signaling the initiation of myelination or in enhancing
the rate of myelin synthesis after lesion formation
[38-41].
Progesterone is an excellent candidate molecule for
neuroprotection and myelin repair, because it easily
crosses the blood-brain barrier and exerts concerted
beneficial influences on multiple processes [42]. The
roles of the classical progesterone and non-classical
GABA (A) receptors have been reported previously via
observations in sciatic nerve and/or Schwann cells in
the presence of these receptors [43]. On the basis of the
observations in Schwann cell cultures, neuroactive ster-
oids have been reported to stimulate P0 expression
through classical progesterone receptor and PMP22
expression through GABA (A) receptor, respectively
[44]. However, the direct interrelationship between anti-
nociceptive effects and underlying mechanisms of neu-
roprotective action needs to be further explored.
Antinociceptive effects of progesterone
Our present data demonstrate that a daily administra-
tion of progesterone produces a significant anti-allody-
nic effect. Interestingly, delayed and prolonged
significant anti-allodynic effects were observed after the
final administration of progesterone in our rat model.
These results suggest that treatment with progesterone
produces not only early anti-nociception but also
delayed and prolonged anti-nociception. Accumulating
behavioral evidence supports the antinociceptive effects
of progesterone. The intrathecal administration of 3a,
5a-tetrahydroprogesterone (3a,5 a-THP) suppresses the
thermal and mechanical nociceptive threshold in rats
with neuropathic pain [45]. Molecular and biochemical
investigations have also revealed an up-regulation of
enzymatic pathways (cytochrome P450scc and 3a-
hydroxysteroid oxidoreductase) leading to 3a,5a-THP
biosynthesis in the dorsal horn [45-47] because choles-
terol is converted to progesterone by cytochrome
P450scc and 3b-hydroxysteroid dehydrogenase inside
the steroidogenic mitochondria. Prolonged treatment
with progesterone or its metabolites also show beneficial
effects upon peripheral nerves at the neurophysiological,
functional, and neuropathological levels in a model of
diabetic neuropathy induced by an injection of strepto-
zotocin in rats [6]. Progesterone may attenuate nocicep-
tion and associated inflammatory responses via NK-1R
(substance P receptor)-dependent pathways in vitro and
in vivo studies [48].
Our present findings also demonstrate that daily treat-
ments with progesterone produce significant anti-allody-
nic effects in the rats with LPA-induced demyelination
without any motor impairment. Moreover, our current
analyses further demonstrate that progesterone
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duced by LPA injection. Although our data do not indi-
cate a direct interrelationship between a blockade of
demyelination and antinociception, progesterone treat-
ment seems to produce antinociception either by pre-
venting demyelination or by promoting remyelination in
our LPA-induced trigeminal neuropathic pain model.
Hence, new strategies for developing treatments against
trigeminal neuralgia like nociception, which simulta-
neously potentiate axonal regeneration, promote remye-
lination, or the recovery of nerve functions, are needed.
Conclusions
In conclusion, the present analyses demonstrate that
LPA injections into the trigeminal nerve root produce
prolonged nociceptive behavior, including mechanical
allodynia and hyperalgesia, in the trigeminal territory in
our subject rats. The LPA-treated rats showed severe
demyelination of the trigeminal nerve root. The subcu-
taneous administration of progesterone not only attenu-
ated mechanical allodynia but also recovered
demyelination or promoted remyelination in these ani-
mals. These results suggest that progesterone produces
antinociceptive effects through neuroprotective action.
Hence, progesterone has potential utility as a novel ther-
apy for trigeminal neuralgia-like pain relief at an appro-
priate managed dose and is therefore a possible future
treatment strategy for improving the recovery from
injury.
Methods
Animals
Experiments were carried out using male Sprague-Daw-
ley rats weighing between 180 and 210 g. The animals
were maintained in a temperature-controlled room (23
± 1°C) with a 12/12 hour light-dark cycle. All proce-
dures involving the use of the animals were approved by
the Institutional Animal Care and Use Committee of
the School of Dentistry, Kyungpook National University,
and were carried out in accordance with the ethical
guidelines for the investigation of experimental pain in
conscious animals proposed by the International Asso-
ciation for the Study of Pain.
Development of animal model by LPA injection into the
trigeminal nerve root
Surgical procedures were performed under pentobarbital
sodium (40 mg/kg, i.p.) anesthesia. Anesthetized rats
were mounted on a stereotaxic frame (Model 1404;
David Kopf Instruments, Tujunga, CA) for LPA injec-
tion into the left trigeminal nerve root. A 3 μLv o l u m e
of LPA (1 nmol) was injected into the trigeminal nerve
root through a glass micropipette (tip diameter 50 μm)
connected to a 10 μL Hamilton syringe (31 gauge) for
1 0s e c .T h es i t eo fi n j e c t i o nw a s7 . 2m mp o s t e r i o rt o
the bregma, 2.8 mm lateral from the midline, and 9.6
mm ventral from the surface of the skull. Ten minutes
later, the glass micropipette was withdrawn, the wound
was sutured, and a local anesthetic ointment was
applied. After each experiment, the rats were intracar-
dially perfused with 100 ml of heparinized normal saline
followed by 500 ml of freshly prepared fixative solution
under deep anesthesia with sodium pentobarbital (80
mg/kg, i.p.). After perfusion, the LPA injection site was
identified using a stereoscope. Only data obtained from
rats with injection sites clearly within the trigeminal
nerve root were used in the behavioral analysis. LPA
was purchased from Biomol and dissolved in 0.25%
methanol in saline.
General procedures for behavioral testing
Rats were randomly assigned to one of three groups. In
the LPA-treated group (n = 16), the animals received an
LPA injection into the trigeminal nerve root. In the con-
trol group, the rats received a vehicle injection (n = 8).
Behavioral responses were also examined in a naïve
group (n = 7) that did not receive any surgery or treat-
ments. All behavioral tests were conducted between
0700 and 1800 hours. Rats were tested 3 days before
and at 3, 7, 10, 14, 17, 21, 24, 30, 40, 55, 70, 85, 100,
130 and 160 days after the LPA injection. We measured
the body weights of the animals after behavioral moni-
toring and returned them to their cages. All behavioral
responses were measured by an experimenter in a blind
fashion.
Evaluation of orofacial mechanical allodynia
To conduct behavioral observations, each rat was placed
in a customized observation cage which was then placed
in a darkened and noise-free room. The animals were
then acclimated for at least 30 min. Withdrawal beha-
vior, produced by 10 successive trials of constant air-
puff pressure (4 sec duration, 10 sec intervals), was then
examined in freely moving rats, as described previously
[31,49,50]. The intensity and intervals of the air-puff
pressure were controlled with a pneumatic pump mod-
ule (BH2 system; Harvard Apparatus, Holliston, MA).
The air-puffs were applied through a 26-gauge metal
tube (length, 10 cm) located 1 cm from the skin at a 90°
angle. Thresholds were determined through the air-puff
pressure at which each rat responded in 50% of the
trials. The cut-off pressure for the air-puffs was 40 psi.
The naïve rats did not respond to a pressure of less
than 40 psi. A significant decrease in air-puff thresholds
compared with the pre-operative values was defined as
mechanical allodynia.
Evaluation of orofacial mechanical hyperalgesia
Mechanical hyperalgesia was assayed using a pin-prick
test following the same strict rule of habituation and
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previously [31,50]. Briefly, the rats were left to adapt to
the observation cage for 30 min prior to the actual sti-
mulation. During this period, an experimenter reached
into the cage every 30 sec to touch the walls of the cage
with a plastic rod, similar to those used to induce pain,
as previously described [51]. After the rats became
accustomed to the reaching movements, a series of
mechanical stimulations were conducted. A blunt acu-
puncture needle (Needle No. 3, Serine, Japan) was
applied until the needle was slightly bent (the skin was
dimpled but not penetrated). The rat response to the
stimuli was scored on an ordinal scale [31,49,50] as fol-
lows: no response, 0; detection, 1; detection and with-
drawal, 2; detection, withdrawal, and escape or attacking
movements, 3; as for response 3, but with prolonged
facial grooming (> 3 strokes), 4.
Evaluation of orofacial thermal hyperalgesia
Each rat was placed in a customized cylinder-type
acrylic rodent restrainer (height 40 mm-60 mm, length
70-120 mm) for the evaluation of thermal hyperalgesia.
T h ec a g e sh a dah o l ei nt h et o ps ot h a tt h eh e a dc o u l d
receive thermal stimulation and produce a head with-
drawal action. Each cage was placed in a darkened and
noise-free room and the animals were habituated for at
least 30 min prior to the start of the experiment. After
radiant heat was applied, the head withdrawal time was
determined as described in previous studies [31,52]. The
application of heat stimuli was performed using an
infrared thermal stimulator (Infrared Diode Laser, LVI-
808-10; LVI tech, Seoul, Korea). The power and current
of the thermal stimulator were adjusted to 11 W and
18.1 A, respectively. This intensity of the thermal stimuli
produced stable latencies of approximately 12 sec for a
10 cm distance from the heat source to the vibrissa pad.
Each rat received two stimuli and the inter-stimulus
interval for each trial was at least 5 min. A cut-off time
of 20 seconds was used in these experiments to prevent
possible tissue damage.
Morphological investigations
Under deep anesthesia with sodium pentobarbital (80
mg/kg, i.p.), rats (n = 6) were intracardially perfused
with 100 ml of heparinized normal saline, followed by
500 ml of 4% paraformaldehyde in 0.1 M phosphate
buffer (PB, pH 7.4) on postoperative day 14 or 160.
After perfusion, the LPA injection site was identified.
The trigeminal nerve root was then removed, postfixed
in the same fixatives overnight, and then embedded in
paraffin and sectioned (4 μmt h i c k )f o rl i g h tm i c r o -
scopy. Sections were stained with luxol fast blue,
which identifies the myelin sheaths of the axons. The
histology of each section was examined under a light
microscope.
Evaluation of antinociceptive and neuroprotective effects
of progesterone
To investigate the antinociceptive effects of progester-
one, we administered this hormone subcutaneously in
LPA-treated animals. Progesterone (8, 16 mg/kg/day)
was injected beginning on operative day for five conse-
cutive days. This concentration of progesterone was
shown previously to recover behavioral performance in
rats after medial frontal cortical contusions [53]. After
these daily treatments, changes in the air-puff thresholds
were measured at 30, 60, 120, 180 min, and 24 hours.
We also tested for any delayed anti-allodynic effects of
progesterone after the fifth treatment. To investigate
neuroprotective effects of progesterone following the
final administration of progesterone at 16 mg/kg/day,
changes in P0 or PMP 22 immunoreactivity were exam-
ined. Progesterone was purchased by Sigma and dis-
solved in 200 μl sesame oil.
Immunohistochemical staining
After the fifth treatment with progesterone, some of the
rats (n = 5 per group) were perfused through the
ascending aorta with 0.9% saline, followed by 4% paraf-
ormaldehyde in 0.1 M PB. The trigeminal nerve roots
were then dissected out, postfixed in the same fixative
at 4°C overnight, and then replaced with 30% sucrose in
0.1 M PB overnight. Transverse frozen sections (free-
floating, 18 μm) were performed by a cryostat and pro-
cessed for immunohistochemistry. All sections were
blocked with 5% goat serum in PBS containing 0.2%
Triton X-100 for 1 h at room temperature. Subse-
quently, they were incubated overnight at 4°C with rab-
bit polyclonal anti-P0 (1:500; Abcam, Cambridge, UK)
or rabbit polyclonal anti-PMP22 (1:500; Abcam). The
sections were then incubated with horseradish peroxi-
dase (HRP)-conjugated anti-mouse and anti-rabbit anti-
body (Vector Laboratories, Burlingame, CA) for 2 h at
room temperature. The sections were next covered with
DAB solution (Vector Laboratories) for 10 min and
observed under a light microscope (Axioplan; Zeiss,
Oberkochen, Germany).
Western blotting
Rats (n = 5 per group) were sacrificed by decapitation
after their fifth treatment with progesterone. The tri-
geminal nerve root including the injection site was
immediately removed and quickly frozen in liquid nitro-
gen. Samples were sonicated with Biorupture (Cosmo
Bio., Tokyo, Japan) in a lysis buffer containing protease
and a phosphatase inhibitor cocktail (Thermo Scientific,
Rockford, IL). Protein concentrations in the samples
were measured using a fluorometer (Invitrogen, Carls-
bad, CA). For western blotting, total proteins (30 μg)
were separated in a 4-12% gradient NuPAGE Novex
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membrane using an iBlot Dry blotting system (Invitro-
gen). The membranes were then blocked with 5% non-
fat milk in TBS with 0.1% Tween 20 for 1 h at room
temperature and then incubated with P0 (1:2000,
Abcam) or PMP 22 (1:2000, Abcam) at 4°C overnight.
The blots were subsequently incubated with goat anti-
rabbit horseradish peroxidase for 1 h at room tempera-
ture. Membranes were developed using the SuperSignal
West Femto substrate (Pierce, Rockford, IL), and
exposed to X-ray film. We used the ImageJ analysis sys-
tem (NIH, Bethesda, MD) to quantify specific bands.
Rotarod test
Changes in motor performance after the subcutaneous
administration of progesterone were measured using a
rotarod (Ugo Basile, Comerio-Varese, Italy), as described
previously [54,55]. The rotarod speed was set at 12 rpm
with a maximum time spent on the rod set at 180 sec.
The rats received two or three training trials on two
separate days prior to testing for acclimatization. On the
testing day, the resting response was examined. After
the subcutaneous administration of progesterone (16
mg/kg/day), the time course of the motor performance
was examined.
Statistics
Differences between groups were compared using analy-
sis of repeated measures analysis of variance (ANOVA)
followed by LSD post hoc analysis. Comparisons
between two means were performed using the Student’s
T-test. In all statistical comparisons, P < 0.05 was used
as the criterion for statistical significance. All data are
presented as the mean ± SEM.
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